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Dysregulated Epstein-Barr virus infection in patients with CIDP
Abstract
Ubiquitous viruses have frequently been proposed as a cause or trigger of chronic immune-mediated
diseases. Infections are reported to be temporally associated with clinical exacerbations in patients with
chronic inflammatory demyelinating polyneuropathy (CIDP). We examined immunological parameters
of herpesvirus infections in untreated patients with CIDP compared to demographically matched
controls. Patients with CIDP were uniformly seropositive for EBV-specific IgG and the disease was
associated with a moderately enhanced IgG reactivity to EBV-encoded antigens expressed during both
B cell transformation and productive viral replication. Moreover, cellular EBV copy numbers were
3-fold increased in patients with CIDP. In contrast, humoral immune responses to other herpesviruses
(HCMV, HSV) as well as virus-specific IgM responses were unchanged in CIDP. These data indicate
that host-pathogen interactions during chronic EBV infection are dysregulated in treatment-naïve
patients with CIDP.
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Abstract 
 
Ubiquitous viruses have frequently been proposed as a cause or trigger of 
chronic immune-mediated diseases. Infections are reported to be temporally 
associated with clinical exacerbations in patients with chronic inflammatory 
demyelinating polyneuropathy (CIDP). We examined immunological 
parameters of herpesvirus infections in untreated patients with CIDP 
compared to demographically matched controls. Patients with CIDP were 
uniformly seropositive for EBV-specific IgG and the disease was associated 
with a moderately enhanced IgG reactivity to EBV-encoded antigens 
expressed during both B cell transformation and productive viral replication. 
Moreover, cellular EBV copy numbers were 3-fold increased in patients with 
CIDP. In contrast, humoral immune responses to other herpesviruses (HCMV, 
HSV) as well as virus-specific IgM responses were unchanged in CIDP. These 
data indicate that host-pathogen interactions during chronic EBV infection are 
dysregulated in treatment-naïve patients with CIDP.  
 
Key words: CIDP, Autoimmunity, Infection, EBV, Herpesvirus 
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Introduction 
Chronic inflammatory demyelinating polyneuropathy (CIDP) is an acquired 
peripheral nerve disorder of autoimmune origin.  Both cell-mediated and 
humoral immune responses directed against incompletely characterized 
peripheral nerve antigens have been considered to contribute to the 
development of CIDP. Detailed clues concerning the initiation and 
perpetuation of the inflammatory demyelinating process in CIDP are, however, 
still sparse (Koller et al., 2005) (Hughes et al., 2006). 
 Infectious pathogens and antiviral immune responses trigger 
autoimmune pathologies in a variety of experimental models (Munz et al., 
2009) and have been reported to be temporally associated with the 
development of neurological deficits in CIDP patients (McCombe et al., 1987) 
(Bouchard et al., 1999). Due to their ability to cause persistent infections that 
periodically reactivate, human herpesviruses such as the alpha-herpesvirus 
herpes simplex virus (HSV), the beta-herpesvirus cytomegalovirus (HCMV) 
and the gamma-herpesvirus Epstein-Barr virus (EBV) are candidate triggers of 
autoimmune diseases development and exacerbation. We previously analyzed 
clinical, laboratory and electrophysiological features in a large cohort of 
patients with CIDP (Tackenberg et al., 2007). Here, we investigated a possible 
association between CIDP and host-pathogen interactions during chronic 
infections with ubiquitous herpesviruses. 
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Patients, Material, and Methods 
 
Patients and Controls. Patient data and serum samples were collected in the 
Departments of Neurology, Philipps-University, Marburg, and Charité 
University Medicine Berlin, Germany. The modified AAN (Saperstein et al., 
2001) and the EFNS criteria (2005) were used for the diagnosis of CIDP 
(Tackenberg et al., 2007). From a total of 66 retrospective patients with 
chronic autoimmune neuropathies, current infection and history of 
immunosuppressive drug treatment 2 months prior to the time of blood 
drawing led to exclusion from the study in 19 cases. Consequently, 34 patients 
(Table 1), who had not received any immunomodulatory or 
immunosuppressive therapy before serum samples were obtained, were 
included in the study. Control serum samples were recruited from the Institute 
of Virology, Humboldt University, Berlin, Germany. Controls were excluded if a 
neurological, haematological or in any kind inflammatory diagnosis was 
suspected (Table 1). We additionally included independent and prospective 
cohorts of untreated patients with CIDP (n = 23) and demographically matched 
healthy controls (n=39) to compare antiviral IgG responses with and cell-
bound EBV titers (Table 1). The study was approved by the local ethics 
committee according to the Declaration of Helsinki.  
 
ELISA. The detection of antiviral IgM and IgG antibodies was performed by 
ELISAs, using commercially available ELISA kits, following the manufacturer’s 
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instructions.Anti-CMV IgM and IgG were assessed using an ELISA kit from 
Medac (Wedel, Germany). Anti-HSV IgM and IgG and anti-EBV IgM in IgG were 
quantified using a kit from Dade Behring (Liederbach, Germany), ELISA plates 
for detection of EBV-specific IgG were coated with a mixture of antigens 
(EBVpooled Ag; Dade Behring, Liederbach, Germany) derived from: (i) lytic early 
antigens (EA), (ii) lytic viral capsid antigens (VCA), and (iii) the latent EBV 
nuclear antigen 1 (EBNA1). Antibody responses to EBV were additionally 
determined with ELISAs coated with EBNA1 only (DiaSorin, Dietzenbach, 
Germany) or VCA only (Bioquant, San Diego, CA). Plates were read in a 
microplate reader (Dynex Technologies, Chantilly, Virginia, USA). 
 
Viral loads. EBV DNA was quantified from PBMCs by quantitative real time PCR 
using a TaqMan PCR kit and a Model 7500 Sequence
 
Detector (Applied 
Biosystems, Foster City, CA) (Lunemann et al., 2008). DNA was extracted from 
PBMCs using the QIAamp DNA Blood Mini Kit (Qiagen) following the 
manufacturer’s protocol. A region from the BamHI W fragment of EBV was 
amplified using primers 5`-GGACCACTGCCCCTGGTAAA-3` and 5`-
TTTGTGTGGACTCCTGGGG-3` and detected with fluorogenic probe 5`-FAM-
TCCTGCAGCTATTTCTGGTCGCATCA-TAMRA-3`. The human bcl-2 gene was 
amplified using primers 5`-CCTGCCCTCCTTCCGC-3` and 5`-
TGCATTTCAGGAAGACCCTGA-3` and detected with fluorogenic probe 5`-FAM-
CTTTCTCATGGCTGTCC-TAMRA-3`. The EBV BamHI W fragment copy 
number per cell was calculated using the formula N=2xW/B, where N is the EBV 
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BamHI W copy number/cell, W is the EBV BamHI W copy number, and B is the 
bcl-2 copy number. All samples were tested in at least duplicate and the mean 
results were determined.  
 
Biostatistical analysis. Fisher’s Exact Test was used to detect categorical 
differences between CIDP patients and controls as well as between subgroups 
of patients. Seroprevalence rates were defined by the ratio of the number of 
individuals with detectable antiviral IgG responses to the total number of 
individuals tested and are presented as percentages The Mann Whitney U test 
was applied to compare antibody titers and cellular EBV titers between 
patients and controls. For all our statistical comparisons, we used PRISMS 
software (Graphpad, San Diegeo, CA).  
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Results  
 
Increased EBV-specific IgG titer in CIDP  
First, we evaluated IgM and IgG antibody responses to EBV-, HCMV-, and 
HSV-encoded antigens in retrospective serum samples from patients with CIDP 
compared to demographically matched controls. The ELISA plate for detection of 
EBV-specific IgG was coated with a mixture of epitopes derived from early 
antigens (EA), viral capsid antigens (VCA), and the EBV nuclear antigen 1 
(EBNA1). To differentiate between predominantly lytic and latent EBV antigen-
specific IgG responses, we additionally employed an EBNA1-IgG specific ELISA. 
The ELISA plate for detection of HCMV-specific and HSV-specific IgM and IgG 
was coated with lysates from virus-infected cells.  
As shown in Figure 1, both patients with CIDP and controls were 
universally infected with EBV (100% vs. 97.7%). HCMV- responses could be 
detected in 70.6% of CIDP patients and 67.4% of control donors, respectively. 
Likewise, the seropositivity rate for HSV infection was similar in CIDP (97.1%) 
and controls (94.2%).  
In contrast, we found that EBV-specific, but not HCMV- or HSV-specific 
IgG titers were significantly higher in the CIDP cohort (p < 0.0001 for pooled lytic 
and latent EBV antigens and p = 0.02 for EBNA1) (Fig. 1). The increase in IgG 
activity was stronger if EBNA1 was pooled with lytic antigens than for EBNA1 
only suggesting a predominant increase of antibody responses to viral gene 
products associated with lytic replication.  
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We additionally analyzed the correlation of virus-specific antibody 
activities with the disease by splitting the antibody titers into tertiles (low, 
medium, and high activity) (Sundstrom et al., 2004).  As depicted in Table 2, high 
IgG activity in response to both pooled EBV antigens and EBNA1 was 
significantly more frequent in the patient cohort, and a highly enhanced EBV-
specific humoral immune response was associated with CIDP with calculated 
odds ratios of 5.1 for pooled EBV antigens (95% CI, 2.2 – 12.2; p<0.001) and 3.1 
for EBNA1-binding IgG (95% CI, 1.3 – 7.4; p=0.014). 
In contrast to our findings on EBV-specific antibody responses, CIDP 
patients did not differ from controls in the prevalence of IgG against other 
ubiquitous human herpesviruses, i.e. HCMV and HSV (Figure 1). Likewise, 
HCMV- and HSV-specific IgG antibody activities, regardless of magnitude, had 
no or negligible effects on the risk for CIDP (Table 2). Furthermore, the 
prevalence of IgM antibodies did not statistically differ between both cohorts 
for any of the viruses tested (Suppl. Table 1).   
Altogether, these data show that patients with CIDP, compared to healthy 
EBV carriers, exhibit specifically elevated IgG responses towards EBV-encoded 
antigens expressed during both B cell transformation and productive viral 
replication, whereas immune responses against HCMV and HSV and antiviral 
IgM responses are similar in both groups.  
  
EBV copy numbers in circulating blood cells are threefold increased in 
CIDP  
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 We next quantified levels of cell-bound viral genomes in circulating blood 
cells in an independent prospective cohort of untreated CIDP patients and 
demographically matched healthy blood donors (Table 1). Notably, IgG 
responses to lytic EBV antigens, i.e. VCA, but not to HCMV were also 
moderately increased in this CIDP cohort (Figure 2A). EBV DNA was detectable 
in 7/12 (58%) healthy donors and in 11/12 (92%) CIDP patients, from whom 
PBMCs were accessible for viral load quantification (Lunemann et al., 2006). As 
depicted in Figure 2B, CIDP patients showed 3-fold increased levels of cell-
associated EBV DNA copies (mean 626 for HD vs. 2,008 for CIDP per 106 
PBMC, respectively; p = 0.03). 
 We finally stratified our CIDP patient population into different subgroups 
according to the disease phenotype and the disease course as shown in Table 
1 as well as depending on the severity of the disease as assessed by the 
modified Rankin disability scale, the response to immunomodulatory treatment 
as defined as clinical improvement of at least one point on the modified Rankin 
scale for at least one week. Significant differences in the prevalence or level of 
IgG responses to any of the herpesviruses tested in this study or to cell-bound 
EBV titers were not detected in any of these subgroups. 
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Discussion 
Our study demonstrates that untreated patients with CIDP patients show 
increased IgG responses to pooled lytic and latent EBV antigens which are 
involved in both B cell transformation and productive viral replication, as well as 
higher levels of cell-associated viral genomes in circulating blood cells. These 
data indicate that host-EBV interactions are dysregulated in patients with CIDP 
and suggest a possible link between the immunopathogesis of CIDP and EBV 
infection.  
 Viral infections are believed to be important triggers of autoimmune 
diseases. However, the flip side of the idea that autoimmunity is driven by viral 
infections is that autoreactive immune responses, or even only a predisposition 
to the development of these responses, might affect the ability of the host to 
control infections and to regulate antiviral immune responses.  EBV is strongly 
regulated by and responsive to the biology of its main host cell, the B cell, and it 
has previously been proposed that B cell dysfunction in autoimmune diseases 
associated with prominent autoantibody production interferes with regulatory 
mechanisms of EBV persistence (Gross et al., 2005) (Lunemann et al., 2008) 
(Munz et al., 2009).  
 Gross et al. (Gross et al., 2005) reported that patients with SLE show up 
to 40-fold increased EBV loads in circulating blood cells associated with aberrant 
expression of viral lytic (BZLF1) and latency (latency membrane proteins 1 and 
2a) genes in memory B cells indicating that higher viral loads are indeed 
associated with increased lytic replication. 
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Patients with rheumatoid arthritis (RA) show 7-fold higher levels of EBV 
copy numbers in circulating blood cells and increased IgG and T cell responses 
to both lytic and latent EBV-encoded antigens (Lunemann et al., 2008). Patients 
with RA exhibit defects in central B cell tolerance mechanisms, resulting in higher 
frequencies of circulating autoreactive B cells (Samuels et al., 2005) (Meffre and 
Wardemann, 2008). Notably, rheumatoid factor, which consists of autoantibodies 
against the constant region of IgG Abs and can be detected in the vast majority of 
patients was shown to induce EBV replication via B cell receptor stimulation in 
vitro (Yang et al., 2004). It is therefore conceivable that higher viral loads and 
EBV-specific immune responses result, at least in part, from frequent B cell 
autoantigen recognition in RA.  
Patients with CIDP show impaired B cell expression of the inhibitory Fc- 
receptor (FcRIIB) which represents a late checkpoint during peripheral B cell 
development. FcRIIB signaling prevents memory B cells with low affinity or self-
reactive receptors from entering the germinal center and becoming antibody 
producing plasma cells (Nimmerjahn and Ravetch, 2008). Indeed, humoral 
immune responses are thought to play a crucial role in mediating peripheral 
nerve damage in CIDP (Meyer zu Horste et al., 2007). Similar to our previous 
study in patients with RA (Lunemann et al., 2008), we observed increased IgG 
responses to both lytic and latent EBV antigens and moderately increased viral 
loads in treatment-naïve patients with CIDP. Collectively, these data suggests 
that the behavior or regulation of mature B cells in B cell-driven autoimmune 
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diseases alters the state of EBV persistence, leading to increased viral 
replication and anti-viral immune responses.  
 Even though elevated EBV-specific immune responses might represent an 
epiphenomenon in response to increased antigen load in circulating blood cells, 
one cannot exclude the possibility that these might augment T cell and antibody 
mediated tissue damage and contribute to a local proinflammatory environment 
by recognizing EBV gene products in inflamed peripheral nerves. Although we 
consider this possibility unlikely since immunopathological studies on biopsied 
sural nerves from patients with CIDP found that myeloid and T cells are the main 
components of inflammatory infiltrates (Bonetti et al., 1993) (Matsumuro et al., 
1994), the frequency of B lineage cells including plasma cells within affected 
nerves has so far not been thoroughly evaluated.  
 In conclusion, we have demonstrated perturbations of EBV infection in 
treatment-naïve patients with CIDP. Immune responses (IgM and IgG) to other 
herpesviruses (HCMV, HSV) were unchanged in CIDP. Similar findings have 
been reported in patients with autoimmune diseases with a strong humoral 
immune component such as SLE (Gross et al., 2005) and RA (Lunemann et al., 
2008) illustrating the sensitivity of the virus to perturbations of the immune 
system.  Future studies will need to address whether specific B cell abnormalities 
in CIDP correlate with changes in the regulation of EBV infection and whether 
EBV-specific immune responses correlate with clinical disease activity and 
progression in CIDP over time.   
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Figure Legends 
 
Figure 1. Increased EBV-specific IgG responses in untreated patients 
with CIDP. ELISA plates for detection of EBV-specific IgG were coated with a 
mixture of epitopes (EBVpooled Ag) derived from lytic early antigens (EA), lytic 
viral capsid antigens (VCA), and the latent EBV nuclear antigen 1 (EBNA1) or 
with EBNA1 only. ELISA plates for detection of HCMV-specific and HSV-
specific antibody responses were coated with lysates from virus-infected cells. 
IgG responses were determined in 34 treatment naive patients with CIDP and 
86 healthy controls. Shown are means and SEM of arbitrary units (AU) and 
titers (for HSV) of anti-herpesviridae IgG. IgG seroprevalence rates (%) are 
given below diagrams.  
 
Figure 2. Higher IgG response to EBV-derived lytic antigens is 
associated with higher viral loads in circulating blood cells. A: 
Moderately increased IgG response to lytic EBV antigens but not HCMV viral 
lysates in an independent cohort of treatment naïve patients with CIDP (n=23) 
compared to healthy controls (n=39). Seroprevalence rates (%) are given 
below diagrams. B: Higher cell-bound EBV titers in untreated patients with 
CIDP (n=12) compared to healthy EBV carriers (n=12). Shown are means and 
SEM of viral genome copy numbers per 106 PBMCs. 
 
 
Table 1. Demographic and clinical characteristics of patients and controls 
for the analysis of EBV-. HCMV-, and HSV-specific antibody responses.  
 
 CIDP 
n=34 
controls 
n=86 
Age  
(years±sd; range) 
61.5±15.6 
(11 ↔ 81) 
60.3±13.9 
(17 ↔ 89) 
Duration of Symptoms  
(years±sd; range) 
4.9±4.6 
(0 ↔ 19) 
n.a. 
Male to Female Ratio 5.8 5.1 
Fulfilling modified AAN criteria 34 (100 %) n.a. 
Fulfilling EFNS criteria 34 (100 %) n.a. 
Clinical Coursea  n.a. 
RRa (n) 7 (20.6 %)  
PPb (n) 22 (64.7 %)  
monophasic (n) 5 (14.7 %)  
Clinical Pattern  n.a. 
symmetric (n) 31 (91.2 %)  
asymmetric (n) 3 (8.8 %)  
sensorimotor (n) 27 (79.4 %)  
sensory (n) 7 (20.6 %)  
predominantly distal (n) 20 (58.8 %)  
predominantly proximal (n) 14 (41.2 %)  
Treatment Responsec (n) 22 (81.5 %) n.a. 
 
a – relapsing-remitting, b – primary-progressive, c – 27 patients received 
immunosuppressive or immunomodulatoring treatment, i. e. intravenous 
immunoglobulins, corticosteroids, azathioprine, and/or mycophenolate mofetil 
following serum sample collection.  
 
 
Table 2. Seroprevalence of herpesvirus-specific IgM and IgG antibodies in patients with CIDP and control 
subjects 
 
 EBVAg-IgG EBV-
EBNA1-IgG 
CMV- 
IgG 
HSV- 
IgG 
VCA- 
IgM 
CMV- 
IgM 
HSV- 
IgM 
Patients 
n = 34, n (%) 
34  
(100%) 
31  
(91.18%)  
24  
(70.59%) 
33  
(97.06%) 
0 
(0%) 
4  
(11.76%) 
1  
(2.94%) 
Control Subjects  
n = 86, n (%) 
84  
(97.67%) 
75  
(87.21%) 
58  
(67.44%) 
81  
(94.19%) 
2 
(2.33%) 
3  
(3.49%) 
1  
(1.16%) 
 
EBVAg: includes a defined mixture of relevant EBV antigens (Early Antigens, Viral Capsid Antigen, and Epstein-Barr Virus 
Nuclear Antigen 1 (EBNA1)). 
 
Table 3. Increased EBV-specific antibody titers in patients with CIDP. The number of seropositive patients and 
controls showing low, medium or high antiviral IgG-activities were compared using Fisher’s exact test. The risk of activity 
against virus on being positive for CIDP was estimated in terms of odds ratios (OR) and 95% confidence interval (95% 
CI).  
 
Antibody Titre 
tertiales  
Arbitrary units  Prevalance,        
n (%) 
Cases 
Prevalance,    
n (%) 
Controls 
P-value* OR 95% CI 
EBVmixture-IgG low < 130 4 (11.8) 31 (36.9) 0.007 0.2 0.073-0.708 
medium 130-280 9 (26.5) 33 (39.3) 0.300 0.5 0.231-1.340 
high > 280 21 (61.8) 20 (23.8) < 0.001 5.1 2.220-12.150 
EBV-EBNA-1-IgG low <  64 4 (12.9) 21 (28.0) 0.132 0.3 0.119-1.22 
medium 64-148 10 (32.3) 33 (44.0) 0.286 0.6 0.251-1.462 
high > 148 17 (54.8) 21 (28.0) 0.014 3.1 1.310-7.444  
CMV-IgG low < 4.47 5 (20.8) 22 (37.9) 0.197 0.4 0.141-1.319 
medium 4.47-10 7 (29.2) 17 (29.3) 1.000 0.9 0.349-2.83 
high > 10 12 (50.0) 19 (32.8) 0.210 2.1 0.778-5.416 
HSV-IgG low < 1.7x10
3
 16 (48.5) 31 (38.3) 0.402 1.5 0.671-3.44 
medium 1.7x10
3
-2.6x10
3
 8 (24.2) 23 (28.4) 0.817 0.8 0.312-2.048 
high >  2.6x10
3
 9 (27.3) 27 (33.3) 0.658 0.8 0.307-1.835 
 
HCMV-IgG
CONTROLS CIDP
0
2
4
6
8 p = 0.09
EBV-IgG
CONTROLS CIDP
0
100
200
300
400
500 p = 0.0002
EBNA1-IgG
CONTROLS CIDP
0
50
100
150 p = 0.017
HSV-IgG
CONTROLS CIDP
0
10000
20000
30000 p = 0.707
A 
B 
EBNA1-IgG4
OIND CIDP
0
500
1000
1500 p = 0.69
7/20 8/20
EBNA1-IgG1
OIND CIDP
0
500
1000
1500 p = 0.04
17/20 18/20
EBNA1-IgG3
OIND CIDP
0
500
1000
1500
0/20 0/20
n.d. n.d.
EBNA1-IgG2
OIND CIDP
0
500
1000
1500 p = 0.22
4/20 2/20
